| Company Name | Sanofi |
|---|---|
| Protocol Number | OBS18067 |
| Title of Study | PROphylactic Efanesoctocog Alfa Therapy Evaluated for Critical Joint Health in Hemophilia A Treatment: The PROTECT-ALT Study |
| Primary Objective | To describe the effectiveness of efanesoctocog alfa prophylaxis on joint health outcomes over 5 years. |
| Number of Sites | 10 |
| Period of Study | From：3/11/2024 to：1/15/2032 |
| Number of Patients | 120人 |
| IRB Approval Date | NTUH: 9/6/2024 TSGH: 7/31/2024 TMUH: 7/25/2024 CGMH-LK: 9/18/2024 CSMUH: 6/28/2024 CMUH: 10/15/2024 TCVGH: 10/16/2024 CCH: 7/11/2024 KMUH: 8/16/2024 CGMH-KH: 9/18/2024 |
| Publication Plan / Date | 2026 |
